CSL partners with Alentis on kidney liver drug
CSL will pay $355 million upfront and up to $1.2 billion in milestones to co-develop and commercialize Alentis' Lixudebart for rare kidney and liver diseases.
Palanor Wire · composed from 3 outlets · every claim links to its sources
What happened
CSL announced an exclusive global partnership with Alentis Therapeutics on October 5, 2026. 2 CSL will pay $355 million upfront and up to $1.2 billion in future payments. 3 The companies will co-develop and commercialize Lixudebart for rare kidney and liver diseases. 123 Lixudebart is an anti-fibrosis drug that has shown promising results in clinical trials. 13
Sources · 3
[1]CSL Forms Exclusive Alliance with Alentis Therapeutics to Develop Lixudebart (CSL)
gurufocus.com · via Marketaux
[2]CSL to pay $355M upfront to co-develop Alentis’ kidney and liver drug
Endpoints News
[3]Global Collaboration Between CSL and Alentis to Develop and Commercialize Lixudebart for Treating Rare Kidney and Liver Diseases
chinamoneynetwork.com · via Marketaux
Matched signals
Lattice signals Numen pinned to this story at publish time.
No matched signals on this story.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →On X right now
Top engagement posts about this topic, ranked by likes + retweets + quotes.
No high-engagement X posts captured for this topic. Either the topic is too quiet or the upstream API was unavailable when this article published.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →Your read
How did this article land?
Three sliders. Optional comment. Anonymous is fine.
Open to anyone. One response per reader.